In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
|Articles|June 15, 2015
Amanda Yopp Discusses the Challenges With Treating Multiple Myeloma Patients
Author(s)Amanda Yopp
Amanda Yopp, NP, Clinical Nurse Educator, Takeda Oncology, discusses the challenges with treating patients with multiple myeloma.
Advertisement
Amanda Yopp, NP, Clinical Nurse Educator, Takeda Oncology, discusses the challenges with treating patients with multiple myeloma.
Advertisement
Related to this article
Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.
Dana-Farber nurse practitioners outline ADC patient selection, sequencing, ILD surveillance, and patient education from JADPRO Live 2026.
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.
FDA approves pirtobrutinib for untreated CLL/SLL without 17p deletion based on BRUIN CLL-313 data. Read key nursing safety takeaways.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
AI Breast Cancer Risk Models Guide Triage and Nurse-Led Patient Counseling
2
Sunvozertinib Now Available in US for Pretreated EGFR Exon 20+ NSCLC
3
What Oncology Nurses Need to Know About ADCs in Breast Cancer
4
Male Breast Cancer: Warning Signs, Biology, and Genetic Testing
5